Global Biologics Market Set To Grow To Over $212bn In 2017

07 August 2017
Pharma

Visiongain has launched a new pharma report Biologics Market Report : Evaluation of Therapeutic Segments Including Monoclonal Antibodies, Insulin, Fusion Proteins, Interferons and Gene Therapies; Prediction of Leading National Markets (US, Japan, EU5 and BRIC); Investigation of Top Products Including Humira, Remicade, Lantus and Enbrel; and Assessment of R&D Including Sirukumab and NurOwn

Biologics (biological drugs) are products derived from living organisms (from sources such as microorganisms, animals and human beings) - including agents obtained directly from living organisms, and products created by recombinant genetic engineering technology. Biologics include a wide range of medicines, including therapeutic proteins, monoclonal antibodies (mAbs) and gene therapies.

Biopharmaceuticals form a vital part of the treatment portfolio for many serious chronic disorders, including cancer, diabetes, hepatitis and autoimmune diseases. This highly lucrative market is set to experience high sales between 2017 and 2027, but will have to adapt to many new challenges along the way.

The lead Visiongain report analyst for this report commented; “Biologics are crucial for the treatment of many serious chronic disorders such as cancer, diabetes, hepatitis and autoimmune diseases. These effective but highly complex therapies come at a price, with some treatments costing more than $75,000 a year. They are able to generate multi-billion dollar revenues, with biologics representing seven out of the top ten best-selling drugs in 2016.

The emergence of biosimilars is set to disrupt this market - although they can be a positive or a negative influence, depending on how companies adapt to their presence. Patents on many leading biologics are due to expire during the forecast period of this report, and payers are eager to cut costs in the face of declining healthcare budgets. As such, this is a crucial period in the history of the global biologics market, one which will determine its long-term future.”

The Global market is highly competitive with many different players entering the market. The report discusses products from leading companies in the market. Notable companies in the Global Biologics market include Abbvie, Amgen, Pfizer, Roche, Biogen, Johnson & Johnson, Merck & Co. and Sanofi amongst others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes ePharmacy Market Report 2021-2031

The growth in online shopping has been driven by a rapid rise in the number of smartphones, broadband connections and innovative payment products, although security remains the biggest concern. With the evolving market dynamics, merchants’ payment needs are also changing.

06 May 2021

Read

Visiongain Publishes Protein Labelling Reagents for Research Use Only (RUO) Market Report 2021-2031

Increasing investment in R&D for proteomics research, by both public and private organizations, is one of the major contributors to the growth of the protein labelling reagents market. The increasing prevalence of chronic diseases is also expected to contribute to the growth of this market.

05 May 2021

Read

Visiongain Publishes Aptamer Technologies Market Report 2021-2031

Over the last few years, the aptamers has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body.

29 April 2021

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drug Market Report to 2031

Rising prevalence of inflammatory bowel disease including Crohn’s disease and ulcerative colitis; raising awareness for IBD in developing countries; escalating investment in drug R&D by pharmaceutical companies; new product launches worldwide, growing chronic diseases healthcare awareness are some of the major factors that boosting the growth of global IBD drugs market.

29 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever